

Sl. No.	State	District	Date of Opening
92.		District Hospital, Garhwa	15.10.2012
93.		District Hospital, Koderma # #	09.01.2013
94.	Tripura (4)	GBP Hospital, Agartala	20.03.2014
95.		IGM Hospital, Agartala	28.09.2014
96.		TMC, Agartala	06.12.2014
97.		Gomati District Hospital	31.03.2015
98.	Maharashtra (1)	HA Campus, Pimpri, Pune	26.07.2014
99.	Madhya Pradesh (5)	AIIMS, Bhopal	30.07.2014
100.		Old Palasia, Indore	13.09.2014
101.		Near Civil Hospital, Chhindwara	25.09.2014
102.		Near Civil Hospital, Narsinghpur	27.09.2014
103.		Near Medical College, Sagar	02.02.2015
104.	Uttarakhand (4)	Doon Hospital, Dehradun \$	09.11.2009
105.		Rishikesh \$	07.03.2013
106.		Vikasnagar \$	07.03.2013
107.		Sahaspur \$	07.03.2013
108.	Uttar Pradesh (1)	Sultanpur	13.12.2014

- # Non-functional as reported by Nodal Officer, Delhi. Efforts are being made to make it functional.
- ## The Nodal Officer of Jharkhand who has recently joined has reported closure of these stores. However efforts are being made to get them reopened.
- \$ Jan Aushadhi stores at Sl. No. 104 to 107 are functional. However medicines are not being procured from BPPI and are being locally procured. Health Department of the State Government is being persuaded to procure the medicines from BPPI.

#### **Pricing of medical devices**

151. SHRI A.W. RABI BERNARD: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether National Pharmaceutical Pricing Authority (NPPA) has asked the medical device companies to reveal the maximum retail price of the medical devices they sell in the country, if so, the details thereof;

(b) whether NPPA has also pointed out the media reports about profit margins on devices like cardiac stents orthopaedic implants etc. leading to patients being charged exorbitant prices; and

(c) if so, the details thereof and the necessary steps taken by Government in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANSRAJ GANGARAM AHIR): (a) to (c) There are 22 medical devices regulated as 'drug' under the Drugs and Cosmetics Act and Rules there under. Out of 22 medical devices, 2 are under price control for which ceiling price have been notified under DPCO, 2013. NPPA has asked the manufacturer/distributor of the medical devices, regulated as drugs, to provide certain information for monitoring of price movement as non-scheduled formulations under DPCO, 2013. DPCO, 2013 provides that no manufacturer/importer I distributor is allowed to increase the MRP of a non-scheduled drug more than ten per cent of MRP during preceding twelve months and where the increase is beyond ten per cent, it shall reduce the same to the level of ten per cent of maximum retail price for next twelve months. Based on information received in Form-V of Schedule II of DPCO, 2013, it is seen that bulk of stents consumed in the country are imported and the difference between landed cost and maximum retail price (MRP) is very high. NPPA *vide* its letter dated 27.03.2015 has submitted a report to the Department on pricing of cardiac stents based on the available information and the study conducted by National Health System Resource Centre (NHSRC).

#### **Regulatory measures by US on Indian drug exports**

152. SHRI DEVENDER GOUD T: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) in view of continuous regulatory measures by US impacting Indian drug exports to US, what alternatives Indian drug manufacturing companies are looking at to stay ahead in generic medicines; and

(b) why cannot our pharma companies explore Africa, Middle East and some of the European countries?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANSRAJ GANGARAM AHIR): (a) In spite of stringent regulatory measures by the US, India is the 4th largest partner of USA in supply of generic medicines with over US\$ 4 billion exports to US during the year 2013-14.

(b) Indian Pharma companies are already exporting to Africa, Middle East and European countries.